Trinity Biotech and Latch Medical Partner on Biosensor-Guided Drug Delivery Using CGM+
TRIB is trading near its 52-week low of $0.31 (15% below the low) on light trading volume (0.1× avg).
Summary
Trinity Biotech announced a strategic collaboration with Latch Medical to combine its CGM+ biosensor with Latch's intradermal drug delivery technology, aiming to create precision therapeutic solutions for metabolic diseases. The company also plans a strategic equity investment in Latch Medical, supported by Perceptive Advisors.
Key Events · M&A and Partnerships · TRIB
-
Strategic Collaboration with Latch Medical
Trinity Biotech will combine its AI-native CGM+ wearable biosensor platform with Latch Medical's Pharma Latch™ intradermal drug delivery technology to explore precision therapeutic solutions for diabetes, obesity, and other metabolic conditions.
-
Planned Equity Investment in Latch Medical
Trinity Biotech has agreed in principle to make a strategic equity investment in Latch Medical, with support from its largest financial investor, Perceptive Advisors. The investment amount was not disclosed.
-
Expansion Beyond Monitoring into Drug Delivery
The collaboration marks a strategic shift for Trinity Biotech, extending its CGM+ platform from continuous glucose monitoring into an integrated metabolic health platform that combines sensing, AI-driven insights, and precision therapeutic delivery.
-
Financial Distress Backdrop
The partnership comes as Trinity Biotech faces a going concern warning, a stock price near its 52-week low, and recent termination of a dilutive equity facility. The collaboration could provide a path to future revenue diversification but does not address immediate cash needs.
Analysis · TRIB · Life Sciences
Trinity Biotech is expanding its CGM+ wearable biosensor platform beyond monitoring into precision drug delivery through a collaboration with Latch Medical. The deal includes a planned equity investment, backed by its largest investor Perceptive Advisors. This moves the company toward an integrated metabolic health platform, potentially opening new revenue streams in diabetes and obesity. However, the company remains under severe financial pressure with a going concern warning and a stock trading near all-time lows, so execution risk is high.
At the time of this filing, TRIB was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $0.31 to $3.44. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.